ArcticZymes, Tataa Ink Sales, Distribution Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian enzymes firm ArcticZymes and Swedish gene expression profiling company Tataa Biocenter today announced a mutual sales and distribution deal covering Europe.

The terms of the agreement calls for Tataa to sell ArcticZymes' heat-labile enzymes for use in contamination control through its sales channels. Tataa will also integrate ArcticZymes' products into its range of courses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.